What is Precigen Interest Expense?
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Precigen's interest expense for the
three
months ended in Dec. 2023 was $ -0.01 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.47 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Precigen's Operating Income for the
three
months ended in Dec. 2023 was $ -23.39 Mil. Precigen's Interest Expense for the
three
months ended in Dec. 2023 was $ -0.01 Mil.
Precigen did not have earnings to cover the interest expense.
The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Precigen Interest Expense Calculation
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.47 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Precigen (NAS:PGEN) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Precigen's Interest Expense for the
three
months ended in Dec. 2023 was $-0.01 Mil. Its
Operating Income
for the
three
months ended in Dec. 2023 was $-23.39 Mil. And its Long-Term Debt & Capital Lease Obligation for the
three
months ended in Dec. 2023 was $5.90 Mil.
Precigen's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as
| Precigen did not have earnings to cover the interest expense. |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Precigen (Precigen) Business Description
Traded in Other Exchanges
Address
20374 Seneca Meadows Parkway, Germantown, MD, USA, 20876
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.
Executives
| Jeffrey B Kindler |
director |
35 E. 62ND ST, NEW YORK NY 10065 |
| Randal J Kirk |
director, 10 percent owner, officer: Chief Executive Officer |
1881 GROVE AVENUE, RADFORD VA 24141 |
| Dean J Mitchell |
director |
C/O BRISTOL MYERS SQUIBB CO, 345 PARK AVE, NEW YORK NY 10164 |
| Helen Sabzevari |
director, officer: President and CEO |
20374 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876 |
| Rutul R Shah |
officer: Chief Operating Officer |
C/O PRECIGEN, INC., 20374 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876 |
| Harry Jr. Thomasian |
officer: Chief Financial Officer |
C/O PRECIGEN, INC., 20374 SENECA MEADOWS PARKWAY, GERMANTOWN, MD 20876 |
| Jeffrey Thomas Perez |
officer: SVP, IP Affairs |
20358 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876 |
| Donald P. Lehr |
officer: Chief Legal Officer |
20374 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876 |
| Fred Hassan |
director |
C/O CARET GROUP,, 1100 HOLLAND DR., BOCA RATON FL 33487 |
| Steven Frank |
director |
20374 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876 |
| Vinita D Gupta |
director |
20374 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876 |
| Robert B Shapiro |
director |
155 WEST BURTON PLACE, #2, CHICAGO IL 60610 |
| Cesar L Alvarez |
director |
C/O PEDIATRIX MEDICAL GROUP, LEGAL DEPT 1301- CONCORD TERRACE, SUNRISE FL 33323 |
| James S Turley |
director |
9 MUIRFIELD LANE, SAINT LOUIS MO 63141 |
| Ares Trading S.a. |
10 percent owner |
ZONE INDUSTRIELLE DE L'OURIETTAZ, AUBONNE V8 1170 |
Precigen (Precigen) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PGEN has been successfully added to your 